The cost-effectiveness of Buccolam® (licensed oromucosal midazolam) for the treatment of acute epileptic seizures in the United Kingdom; A hybrid model solution

 

Publication Type:
Poster


Citation:

Lee D, Batty A, Gladwell D, Brereton N and Tate E. The cost-effectiveness of Buccolam® (licensed oromucosal midazolam) for the treatment of acute epileptic seizures in the United Kingdom; A hybrid model solution. 15th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Berlin, Germany. 3-7 November 2012. Poster PND37.

 


Link to publication ⟶

⟵ Back to Search Results